Istiratumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Istiratumab
Monoclonal antibody
Type?
SourceHuman
TargetIGF1R, ErbB3
Clinical data
SynonymsMM-141
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC8802H13532N2392O2796S58
Molar mass199.5 g/mol g·mol−1

Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.[1]

It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.[2]

References[edit]

  1. ^ Alternative Names: MM-141. "Istiratumab - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
  2. ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL : USAN (CD-106) ISTIRATUMAB" (PDF). Searchusan.ama-assn.org. Retrieved 2017-05-23.